RxDoctor Payments Data

Jill Banatoski, MD

Internal Medicine · Westbrook, CTNPI 1982760542

Payments from drug & device makers

$385in general payments, 2019–2025

Across 27 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$59
  • Novo Nordisk$54
  • Merck$50
  • Pfizer$42
  • Amgen$40
  • AbbVie$36
  • plus $105 from 6 others

What the payments were for

  • Food & beverage$385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$385 in reported general payments places this provider in the 65th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$152,619
Medicare patients
249
Services billed
1,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$100,763
EliquisApixaban71$77,904
JardianceEmpagliflozin62$73,492
TrulicityDulaglutide27$57,944
Repatha SureclickEvolocumab48$51,391
ProliaDenosumab25$43,554
WegovySemaglutide17$22,650
MounjaroTirzepatide14$16,484
FarxigaDapagliflozin Propanediol27$15,879
MyrbetriqMirabegron25$15,778
Dexlansoprazole DrDexlansoprazole15$7,126
Levothyroxine Sodium533$6,161
SynthroidLevothyroxine Sodium59$5,649
Rosuvastatin Calcium327$5,459
Atorvastatin Calcium459$5,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$54$123,41379 claims
PfizerEliquis$42$77,90471 claims
Lilly USA, LLCTrulicity, Mounjaro$59$74,42841 claims
AmgenProlia$40$43,55425 claims
AstraZenecaFarxiga$15$15,87927 claims
AbbVieSynthroid$36$5,64959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Westbrook

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →